Keyphrases
Endometrial Cancer
82%
Ovarian Cancer Patients
73%
Comorbidity
62%
Ovarian Cancer
44%
Cancer Patients
43%
Primary Debulking Surgery
42%
Gynecological Cancer
38%
Neoadjuvant Chemotherapy
32%
Cancer Database
29%
Preoperative Staging
28%
Endometrium
28%
Denmark
25%
Comorbidity Index
22%
Gynecologic Oncology
20%
Preoperative Evaluation
18%
Specialist Training
17%
Multicenter Cohort Study
16%
Poor Survival
15%
Endometrial Carcinoma
15%
Postoperative Complications
14%
Clinical Guide
14%
Randomized Clinical Trial
14%
Preoperative Risk Assessment
14%
Surgical Site Infection
14%
Deep Myometrial Invasion
14%
Infectious Complications
14%
Four-level
14%
High-risk Endometrial Cancer
14%
CA-125 Levels
14%
Tumor Removal
14%
Debulking
14%
Age-specific
14%
Survival Disparities
14%
Long-term Survival
14%
Comparative Cohort Study
14%
Human Epididymis Protein 4
14%
Preoperative Diagnosis
14%
Europe
14%
Postmenopausal Women
14%
Training System
14%
Treatment Delay
14%
Gynaecological Oncologists
14%
Prospective Comparative Study
14%
Nordic Countries
14%
System Delay
14%
Ultrasound
14%
Peri
14%
Diagnostic Strategy
14%
Diagnostic Accuracy
14%
18F-FDG PET-CT
14%
Medicine and Dentistry
Ovarian Cancer
100%
Endometrial Cancer
75%
Debulking Surgery
39%
Cytoreductive Surgery
39%
Neoadjuvant Chemotherapy
33%
Endometrium
28%
Positron Emission Tomography-Computed Tomography
28%
Female Genital Tract Cancer
25%
Gynecological Oncology
25%
Malignant Neoplasm
23%
Neoplasm
20%
Diagnosis
19%
Preoperative Evaluation
18%
Overall Survival
15%
Biological Marker
14%
Atypical Hyperplasia
14%
Endometrial Hyperplasia
14%
Diagnostic Accuracy
14%
Levonorgestrel
14%
CA-125
14%
Intrauterine Device
14%
Cohort Analysis
14%
Debulking
14%
Magnetic Resonance Imaging
14%
Long Term Survival
14%
Human Epididymis Protein 4
14%
Cancer
14%
Postmenopause
14%
Oncologist
14%
Lymph Node Metastasis
10%
Prognostic Factor
10%
Triage
9%
Surgery
8%
Charlson Comorbidity Index
8%
Proportional Hazards Model
8%
Risk Stratification
7%
Non Invasive Procedure
7%
Body Mass Index
7%
Cancer Specific Survival
5%
Survival Analysis
5%
Diabetes
5%